What is the first-line treatment for a JAK2‑mutated polycythemia vera patient?

First-Line Treatment for JAK2-Mutated Polycythemia Vera

All patients with JAK2-mutated polycythemia vera should receive phlebotomy to maintain hematocrit below 45% plus low-dose aspirin (75-100 mg daily), and high-risk patients (age >60 years or prior thrombosis) require the addition of cytoreductive therapy with either hydroxyurea or recombinant interferon-alpha as first-line agents. 1

Risk Stratification Framework

The treatment approach is algorithmically determined by thrombotic risk:

Low-Risk Patients

• Age ≤60 years AND
• No history of thrombotic events

High-Risk Patients

• Age >60 years OR
• Prior thrombotic event (arterial or venous)

Universal First-Line Therapy (All Patients)

Phlebotomy

• Target: Maintain hematocrit <45% (strong evidence from CYTO-PV trial showing 3.91-fold reduction in thrombotic events) 1, 2
• Induction phase: Remove 300-450 mL weekly or twice weekly until target reached
• Maintenance phase: Same volume per session, with intervals determined by hematocrit levels 1

Low-Dose Aspirin

• Dose: 75-100 mg daily 1, 2
• Evidence: ECLAP trial demonstrated significant reduction in cardiovascular death, myocardial infarction, stroke, and venous thromboembolism 2
• Contraindication: Withdraw if major bleeding occurs (most commonly gastrointestinal) 3

Cytoreductive Therapy (High-Risk Patients Only)

Either hydroxyurea OR recombinant interferon-alpha (rIFNα) is recommended as first-line cytoreductive therapy. 1

Hydroxyurea

• Standard first-line choice at any age 1
• Caution: Use conservatively in young patients (<40 years) due to potential long-term leukemogenic concerns, though evidence remains inconclusive 2
• Dosing: Typically 2 g/day, adjusted to response

Recombinant Interferon-Alpha (rIFNα)

• Preferred in young patients requiring long-term treatment 1
• Advantages: Non-leukemogenic, can reduce JAK2V617F allele burden 2
• Note: Not FDA-approved for PV but widely used based on phase II evidence 2

Additional Indications for Cytoreductive Therapy

Even in low-risk patients, cytoreduction should be initiated if any of the following develop:

• Poor tolerance to phlebotomy or frequent phlebotomy requirements 1, 3
• Symptomatic or progressive splenomegaly 1
• Severe disease-related symptoms 1
• Platelet count >1500 × 10⁹/L 1
• Leukocyte count >15 × 10⁹/L 1
• Documented severe tissue iron deficiency with detrimental symptoms (pica, mouth paresthesia, esophagitis, restless legs) that worsens hematocrit when treated with iron supplementation 1

Critical Caveats

Age-Based Considerations

The 2018 European LeukemiaNet guidelines 1 emphasize a "cautionary principle" with hydroxyurea in young patients due to concerns about cumulative exposure over decades, even though definitive leukemogenic risk remains unproven. In patients <40 years requiring cytoreduction, strongly consider rIFNα as first-line. 2

Cardiovascular Risk Management

All patients must have aggressive management of cardiovascular risk factors (hypertension, diabetes, hyperlipidemia, smoking cessation) as these compound thrombotic risk 1, 3

Common Pitfall

Do not use ruxolitinib as first-line therapy. Ruxolitinib is FDA/EMA-approved only for second-line treatment in patients who are hydroxyurea-resistant or intolerant 1. Using it first-line wastes a valuable second-line option and is not guideline-concordant.

Monitoring Hematocrit Target

The CYTO-PV trial definitively established that maintaining hematocrit <45% (not <50%) significantly reduces thrombotic events 2. This is a firm target, not a range.